Anti-AACT antibody [5G3C11] - C-terminal

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The target protein Alpha-1-antichymotrypsin (AACT) also known as ACT is a serpin family member with a mass of approximately 68 kDa. This protein functions as an inhibitor of serine proteases particularly targeting chymotrypsin-like enzymes. AACT is expressed in the liver and secreted into the plasma where it carries out its inhibitory role. It is a significant component of the antiprotease shield in human physiology guarding tissues against proteolytic damage.

Biological function summary

Alpha-1-antichymotrypsin plays a role in regulating protease activity to maintain tissue integrity. AACT forms part of a complex that involves other protease inhibitors and enzymes contributing to the balance of protein breakdown and regeneration. Its presence in the extracellular matrix highlights its structural and protective functions supporting cells against enzyme-mediated degradation.

Pathways

Alpha-1-antichymotrypsin takes part in inflammatory and immune response pathways. It interacts within the acute phase response pathway a system activated during inflammatory events. This protein's relationship with other protease inhibitors such as alpha-1-antitrypsin accentuates its role in controlling proteolytic enzymes that could otherwise propagate unchecked inflammation and tissue damage.

Associated diseases and disorders

Alpha-1-antichymotrypsin associates with neurodegenerative diseases such as Alzheimer's disease and pulmonary disorders. Its elevated levels have been observed in Alzheimer's disease cases where it might participate alongside amyloid-beta precursor protein influencing amyloid plaque formation. In lung-related disorders its collaboration with proteins like elastase can affect tissue breakdown emphasizing its role in maintaining pulmonary health.